Fibromyalgia and work disability: Is Fibromyalgia a disabling disorder?

F. Wolfe,J. Potter

DOI: https://doi.org/10.1016/S0889-857X(05)70277-5

IF: 2.032

1996-05-01

Rheumatic Disease Clinics of North America

Abstract:

What problem does this paper attempt to address?

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

Ying Li,Zhijun Zhan,Xuemin Yin,Shujun Fu,Xiyun Deng

DOI: https://doi.org/10.3389/fonc.2021.731535

IF: 4.7

2021-10-28

Frontiers in Oncology

Abstract:Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, which is characterized by the absence of estrogen receptor (ER) and progesterone receptor (PR) expression and the absence of human epidermal growth factor receptor 2 (HER2) expression/amplification. Conventional chemotherapy is the mainstay of systemic treatment for TNBC. However, lack of molecular targeted therapies and poor prognosis of TNBC patients have prompted a great effort to discover effective targets for improving the clinical outcomes. For now, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi’s) and immune checkpoint inhibitors have been approved for the treatment of TNBC. Moreover, agents that target signal transduction, angiogenesis, epigenetic modifications, and cell cycle are under active preclinical or clinical investigations. In this review, we highlight the current major developments in targeted therapies of TNBC, with some descriptions about their (dis)advantages and future perspectives.

oncology
Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer

Magham Sai Varshini,Praveen Thaggikuppe Krishnamurthy,Ramakamma Aishwarya Reddy,Ashish Wadhwani,V.M. Chandrashekar

DOI: https://doi.org/10.2174/0115680096280750240123054936

2024-02-21

Current Cancer Drug Targets

Abstract:Abstract: Triple-negative Breast Cancer (TNBC), the most aggressive breast cancer subtype, is characterized by the non-appearance of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Clinically, TNBC is marked by its low survival rate, poor therapeutic outcomes, high aggressiveness, and lack of targeted therapies. Over the past few decades, many clinical trials have been ongoing for targeted therapies in TNBC. Although some classes, such as Poly (ADP Ribose) Polymerase (PARP) inhibitors and immunotherapies, have shown positive therapeutic outcomes, however, clinical effects are not much satisfiable. Moreover, the development of drug resistance is the major pattern observed in many targeted monotherapies. The heterogeneity of TNBC might be the cause for limited clinical benefits. Hence,, there is a need for the potential identification of new therapeutic targets to address the above limitations. In this context, some novel targets that can address the above-mentioned concerns are emerging in the era of TNBC therapy, which include Hypoxia Inducible Factor (HIF-1α), Matrix Metalloproteinase 9 (MMP-9), Tumour Necrosis Factor-α (TNF-α), β-Adrenergic Receptor (β-AR), Voltage Gated Sodium Channels (VGSCs), and Cell Cycle Regulators. Currently, we summarize the ongoing clinical trials and discuss the novel therapeutic targets in the management of TNBC.

oncology
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Elisa Agostinetto,Daniel Eiger,Kevin Punie,Evandro de Azambuja

DOI: https://doi.org/10.1007/s11912-021-01038-6

2021-03-24

Current Oncology Reports

Abstract:Triple negative breast cancer (TNBC) accounts for approximately 10–15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging therapeutics for TNBC, describing both previously approved therapies that are currently being repurposed, as well as new target therapies that may improve patient outcomes.

oncology
Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer

Harshada Shewale,Abhishek Kanugo

DOI: https://doi.org/10.2174/0113892010303244240718075729

2024-07-31

Abstract:The truancy of representation of the estrogen, progesterone, and human epidermal growth factor receptors occurs during TNBC. TNBC is recognized for the upper reappearance and has a poorer diagnosis compared with rest breast cancer (BC) types. Presently, as such, no targeted therapy is approved for TNBC and treatment options are subjected to chemotherapy and surgery, which have high mortality rates. Hence, the current article focuses on the scenario of TNBC vital pathways and discusses the latest advances in TNBC treatment, including immune checkpoint inhibitors (ICIs), PARP suppressors, and cancer vaccines. Immunotherapy and ICIs, like PD 1 and PD L1 suppressors, displayed potential in clinical trials (CTs). These suppressors obstruct the mechanisms which allow tumor cells to evade the system thereby boosting the body's defense against TNBC. Immunotherapy, either alone or combined with chemotherapy has demonstrated patient outcomes such as increased survival rates and reduced treatment-related side effects. Additionally, targeted therapy approaches include BRCA/2 mutation poly ribose polymerase inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors, Epidermal growth factor receptor inhibitors, Fibroblast growth factor inhibitors, Androgen Receptor inhibitors, PIK3/AKT/mTOR pathway inhibitors, Cyclin-dependent kinase (CDK) inhibitors, Notch signaling pathway inhibitors, Signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors, Chimeric antigen receptor T (CAR-T) cell therapy, Transforming growth factor (TGF) -β inhibitors, Epigenetic modifications (EPM), Aurora Kinase inhibitors and antibody-drug conjugates. We also highlight ongoing clinical trials and potential future directions for TNBC therapy. Despite the challenges in treating TNBC, recent developments in understanding the molecular and immune characteristics of TNBC have opened up new opportunities for targeted therapies, which hold promise for improving outcomes in this aggressive disease.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Mauricio A. Medina,Goldie Oza,Ashutosh Sharma,L.G. Arriaga,José Manuel Hernández Hernández,Vincent M. Rotello,Jose Tapia Ramirez

DOI: https://doi.org/10.3390/ijerph17062078

IF: 4.614

2020-03-20

International Journal of Environmental Research and Public Health

Abstract:Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, and hence TNBC is managed with conventional therapeutics, often leading to systemic relapse. In terms of histology and transcription profile these cancers have similarities to BRCA-1-linked breast cancers, and it is hypothesized that BRCA1 pathway is non-functional in this type of breast cancer. In this review article, we discuss the different receptors expressed by TNBC as well as the diversity of different signaling pathways targeted by TNBC therapeutics, for example, Notch, Hedgehog, Wnt/b-Catenin as well as TGF-beta signaling pathways. Additionally, many epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors effectively inhibit the TNBCs, but they face challenges of either resistance to drugs or relapse. The resistance of TNBC to conventional therapeutic agents has helped in the advancement of advanced TNBC therapeutic approaches including hyperthermia, photodynamic therapy, as well as nanomedicine-based targeted therapeutics of drugs, miRNA, siRNA, and aptamers, which will also be discussed. Artificial intelligence is another tool that is presented to enhance the diagnosis of TNBC.

public, environmental & occupational health,environmental sciences
Novel Ways of Targeting Triple Negative Breast Cancer (TNBC) with the Latest Research - will it Improve Prognoses

Kulvinder Kochar Kaur

DOI: https://doi.org/10.23880/oajg-16000185

2019-01-01

Open Access Journal of Gynecology

Abstract:Breast Cancer, is the commonest malignancy that gets diagnosed in women, leading to the greatest cancer associated deaths all over the world. Triple negative breast cancer (TNBC) refers to the absence of estrogen, progesterone and HER2 receptors, possesses an aggressive clinical nature, having the high metastases rat es . Thus here in this review we have tried to study the mechanism responsible for the high metastases rates by studying the role of Haematopoietic protein tyrosine phosphatases (HePTP) which had a crucial role in metastases of TNBC through activation of Wn t/β - catenin signaling. Further we examined, how certain regional anesthetics like ropivacaine and levobupivacaine had a protective effect in BC, roles of some novel therapies like those combining embelin (EMB)/TRAIL - HA(hyaluronic acid)/ poly(1,6 - hexanediol ) - diacrylate – β - 5 - hydroxyamylamine(PBAE) - polyethylamine (PEI) as cytotoxix and proapoptotic agents against TNBC, how regulation of miR 122 - 5p that causes aggression via epithelial mesenchymal transition(EMT) in TIMC via suppression of charged multivesicul ar body protein 3(CHMP3)through MAPK signaling might help in controlling TNBC. Further combining thiosemicarbazone compound 4 with cisplatin increased p53 phosphorylation, along with Bax level induction, as well as a decreased Bcl2 protein amounts ,increas ed PARP cleavage and modulated miR expression levels in TNBCs with special overexpression of miR - 125a - 5p ,and miR - 181a - 5p and thus role of miR control utilization by other way by thiosemicarbazone compound 4 targeting TNBC apoptosis might be utilized. More over how combining Src inhibitor dasatinib, with the PARP inhibitor veliparib, and the DNA damaging drug carboplatin in TNBC might prove effective in TNBC. Further role of DDB2 in causing resistance to PARP, combination of PARP with metabolic inhibitors is discussed. Additionally liposomes modified by fructose and RGD had >potential for forming a targeted TNBC therapy, particularly the covalently modified Fru - RGD – Lip, marking them as good liposomes having multiple functions. Thus novel therapies for TNBC wh ich might help in developing novel therapies further for controlling TNBC has been emphasized.
Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Harshita Tiwari,Swati Singh,Sonal Sharma,Priyamvada Gupta,Ashish Verma,Amrit Chattopadhaya,Brijesh Kumar,Sakshi Agarwal,Rajiv Kumar,Sanjeev Kumar Gupta,Vibhav Gautam

DOI: https://doi.org/10.1002/med.22090

2024-10-24

Abstract:Triple negative breast cancer (TNBC) displays a notable challenge in clinical oncology due to its invasive nature which is attributed to the absence of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor (HER-2). The heterogenous tumor microenvironment (TME) of TNBC is composed of diverse constituents that intricately interact to evade immune response and facilitate cancer progression and metastasis. Based on molecular gene expression, TNBC is classified into four molecular subtypes: basal-like (BL1 and BL2), luminal androgen receptor (LAR), immunomodulatory (IM), and mesenchymal. TNBC is an aggressive histological variant with adverse prognosis and poor therapeutic response. The lack of response in most of the TNBC patients could be attributed to the heterogeneity of the disease, highlighting the need for more effective treatments and reliable prognostic biomarkers. Targeting certain signaling pathways and their components has emerged as a promising therapeutic strategy for improving patient outcomes. In this review, we have summarized the interactions among various components of the dynamic TME in TNBC and discussed the classification of its molecular subtypes. Moreover, the purpose of this review is to compile and provide an overview of the most recent data about recently discovered novel TNBC biomarkers and targeted therapeutics that have proven successful in treating metastatic TNBC. The emergence of novel therapeutic strategies such as chemoimmunotherapy, chimeric antigen receptor (CAR)-T cells-based immunotherapy, phytometabolites-mediated natural therapy, photodynamic and photothermal approaches have made a significant positive impact and have paved the way for more effective interventions.
Recent advances in targeted strategies for triple-negative breast cancer

Shuangli Zhu,Yuze Wu,Bin Song,Ming Yi,Yuheng Yan,Qi Mei,Kongming Wu

DOI: https://doi.org/10.1186/s13045-023-01497-3

2023-08-28

Abstract:Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates. Moreover, immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored in the clinic. We summarize recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future.
Enhancement of cellular uptake of ellipticine by insulin preincubation.

J. Oster,W. Creasey

DOI: https://doi.org/10.1016/0014-2964(81)90294-2

1981-10-01

European Journal of Cancer and Clinical Oncology

Abstract:
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer

Élia Cipriano,Alexandra Mesquita

DOI: https://doi.org/10.1177/11782234211002491

2021-01-01

Abstract:Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. Treatment of these patients is highly based on systemic chemotherapy. Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibitors in patients with germline BRCA1/2 mutations (olaparib and talazoparib), immune checkpoint inhibitors in association with chemotherapy if programmed death-ligand 1 positive (atezolizumab plus nabpaclitaxel and pembrolizumab plus chemotherapy [nabpaclitaxel, paclitaxel, and carboplatin plus gemcitabine]), and an antibody-drug conjugate sacituzumab-govitecan in heavily pretreated patients (at least 2 previous lines for the metastatic setting). Combinations using these and other targeted treatment options are under investigation in early and late clinical trials, and we will probably have some practice-changing results in the new future. Other targeted drugs explored in phase II and phase III clinical trials are PI3K/AKT pathway inhibitors and androgen receptor antagonists in patients with alterations in these signaling pathways. The definition of molecular subtypes has been essential for the development of these treatment strategies. Soon, the treatment of metastatic TNBC could be based on personalized medicine using molecular testing for targeted drugs instead of only systemic chemotherapy. The authors present a review of emerging treatment options in metastatic TNBC, focusing on targeted drugs, including the recent data published in 2020.
Data delivery workflow in an academic information warehouse.

S. Erdal,Patrick Rogers,J. Santangelo,Jason Buskirk,M. Ostrander,Jianhua Liu,J. Kamal

2008-11-06

Abstract:The Ohio State University Medical Center (OSUMC) Information Warehouse (IW) collects data from many systems throughout the OSUMC on load cycles ranging from real-time to on-demand. The data then is prepared for delivery to diversity of customers across the clinical, education, and research sectors of the OSUMC. Some of the data collected at the IW include patient management, billing and finance, procedures, medications, lab results, clinical reports, physician order entry, outcomes, demographics, and so on. This data is made available to the users of the IW in variety of formats and methods.
A POSSIBLE CASE OF INSTINCTIVE BEHAVIOR IN THE WHITE RAT.

C. Griffith

DOI: https://doi.org/10.1126/SCIENCE.50.1285.166

IF: 56.9

1919-08-15

Science

Abstract:
Druggable molecular targets of triple-negative breast cancer and prospects of therapeutic application

Cau Nguyen Van

DOI: https://doi.org/10.34071/jmp.2022.4.2

2022-07-01

Journal of Medicine and Pharmacy

Abstract:Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, which is characterized by deficient expression of estrogen receptor, progesterone receptor expression and the absence of human epidermal growth factor receptor 2 (HER2) expression/amplification. For the past few decades, due to the lack of druggable targets, conventional chemotherapy has been the mainstay of systemic treatment for TNBC. However, lack of molecular targeted therapies and poor prognosis of TNBC, much research has been devoted to identifying specific molecular targets that can be utilized for targeted cancer therapy to improve the clinical outcomes. Now, poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates have been approved by FDA for the treatment of TNBC. Moreover, agents that target signal transduction, angiogenesis, epigenetic modifications, and cell cycle are under active preclinical or clinical investigations. In this review, we summarize current significant achievements applied in treatment of TNBC with molecular targeted therapy, immunotherapy, and antibody-drug conjugates and upcoming drugs for triple negative breast cancer will be summarized. Key words: triple-negative breast cancer (TNBC), breast cancer, estrogen

English Else
Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

Nating Xiong,Heming Wu,Zhikang Yu

DOI: https://doi.org/10.3389/fonc.2024.1405491

IF: 4.7

2024-05-28

Frontiers in Oncology

Abstract:Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its aggressive nature, limited treatment options, and poorer prognosis compared to other breast cancer subtypes. This comprehensive review examines the therapeutic and diagnostic landscape of TNBC, highlighting current strategies, emerging therapies, and future directions. Targeted therapies, including PARP inhibitors, immune checkpoint inhibitors, and EGFR inhibitors, hold promise for personalized treatment approaches. Challenges in identifying novel targets, exploring combination therapies, and developing predictive biomarkers must be addressed to optimize targeted therapy in TNBC. Immunotherapy represents a transformative approach in TNBC treatment, yet challenges in biomarker identification, combination strategies, and overcoming resistance persist. Precision medicine approaches offer opportunities for tailored treatment based on tumor biology, but integration of multi-omics data and clinical implementation present challenges requiring innovative solutions. Despite these challenges, ongoing research efforts and collaborative initiatives offer hope for improving outcomes and advancing treatment strategies in TNBC. By addressing the complexities of TNBC biology and developing effective therapeutic approaches, personalized treatments can be realized, ultimately enhancing the lives of TNBC patients. Continued research, clinical trials, and interdisciplinary collaborations are essential for realizing this vision and making meaningful progress in TNBC management.

oncology
The treatment landscape of triple-negative breast cancer

Yi Hu,Chen Wang,Huishi Liang,Jie Li,Qiong Yang

DOI: https://doi.org/10.1007/s12032-024-02456-9

2024-09-01

Medical Oncology

Abstract:Triple-negative breast cancer (TNBC) tumors are biologically aggressive breast cancer. On the molecular level, TNBC is a highly heterogeneous disease; more biotechnologies are gradually being used to advance the understanding of TNBC subtypes and help establish more targeted therapies. Multiple TNBC target-related agents are already approved by the Food and Drug Administration for clinical use, including PI3K/AKT/mTOR inhibitors, PRAP inhibitors, and antibody-drug conjugates. Some innovative approaches, like peptide strategies, also promise to treat TNBC. Currently, the interplay between TNBC tumors and their tumor microenvironment provides a promising prospect for improving the efficacy of immunotherapy. In this review, we summarize the prevalent TNBC subtype methodologies, discuss the evolving therapeutic strategies, and propose new therapeutic possibilities based on existing foundational theories, with the attempt to serve as a reference to further advance tailoring treatment of TNBC.

oncology
Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer

Mazharul Haque,Ritis K. Shyanti,Manoj K. Mishra

DOI: https://doi.org/10.3389/fonc.2024.1431418

IF: 4.7

2024-10-11

Frontiers in Oncology

Abstract:Triple-negative breast cancer (TNBC) is distinguished by negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), making it an aggressive subtype of breast cancer and contributes to 15-20% of the total incidence. TNBC is a diverse disease with various genetic variations and molecular subtypes. The tumor microenvironment involves multiple cells, including immune cells, fibroblast cells, extracellular matrix (ECM), and blood vessels that constantly interact with tumor cells and influence each other. The ECM undergoes significant structural changes, leading to induced cell proliferation, migration, adhesion, invasion, and epithelial-to-mesenchymal transition (EMT). The involvement of EMT in the occurrence and development of tumors through invasion and metastasis in TNBC has been a matter of concern. Therefore, EMT markers could be prognostic predictors and potential therapeutic targets in TNBC. Chemotherapy has been one of the primary options for treating patients with TNBC, but its efficacy against TNBC is still limited. Targeted therapy is a critical emerging option with enhanced efficacy and less adverse effects on patients. Various targeted therapy approaches have been developed based on the specific molecules and the signaling pathways involved in TNBC. These include inhibitors of signaling pathways such as TGF-β, Wnt/β-catenin, Notch, TNF-α/NF-κB and EGFR, as well as immune checkpoint inhibitors, such as pembrolizumab, 2laparib, and talazoparib have been widely explored. This article reviews recent developments in EMT in TNBC invasion and metastasis and potential targeted therapy strategies.

oncology
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy

Ruoning Yang,Yueyi Li,Hang Wang,Taolin Qin,Xiaomeng Yin,Xuelei Ma

DOI: https://doi.org/10.1186/s43556-022-00071-6

2022-03-04

Molecular Biomedicine

Abstract:Abstract Triple negative breast cancer (TNBC) is a subtype of breast cancer, with estrogen receptor, human epidermal growth factor receptor 2 and progesterone receptor negative. TNBC is characterized by high heterogeneity, high rates of metastasis, poor prognosis, and lack of therapeutic targets. Now the treatment of TNBC is still based on surgery and chemotherapy, which is effective only in initial stage but almost useless in advanced stage. And due to the lack of hormone target, hormonal therapies have little beneficial effects. In recent years, signaling pathways and receptor-specific targets have been reported to be effective in TNBC patients under specific clinical conditions. Now targeted therapies have been approved for many other cancers and even other subtypes of breast cancer, but treatment options for TNBC are still limited. Most of TNBC patients showed no response, which may be related to the heterogeneity of TNBC, therefore more effective treatments and predictive biomarkers are needed. In the present review, we summarize potential treatment opinions for TNBC based on the dysregulated receptors and signaling pathways, which play a significant role in multiple stages of TNBC development. We also focus on the application of immunotherapy in TNBC, and summarize the preclinical and clinical trials of therapy for patients with TNBC. We hope to accelerate the research and development of new drugs for TNBC by understanding the relevant mechanisms, and to improve survival.
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

Maryam Nakhjavani,Jennifer E Hardingham,Helen M Palethorpe,Tim J Price,Amanda R Townsend

DOI: https://doi.org/10.4048/jbc.2019.22.e39

2019-01-01

Journal of Breast Cancer

Abstract:Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors. These patients are therefore not given the option of targeted therapy and have worse prognosis as a result. Consequently, much research has been devoted to identifying specific molecular targets that can be utilized for targeted cancer therapy, thereby limiting the progression and metastasis of this invasive tumor, and improving patient outcomes. In this review, we have focused on the molecular targets in TNBC, categorizing these into targets within the immune system such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets. The aim of this review is to introduce and summarize the known targets and drugs under investigation in phase II or III clinical trials, while introducing additional possible targets for future drug development. This review brings a tangible benefit to cancer researchers who seek a comprehensive comparison of TNBC treatment options.

oncology
Recent advances in therapeutic strategies for triple-negative breast cancer

Yun Li,Huajun Zhang,Yulia Merkher,Lin Chen,Na Liu,Sergey Leonov,Yongheng Chen

DOI: https://doi.org/10.1186/s13045-022-01341-0

2022-08-30

Abstract:Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC.

oncology,hematology

Fibromyalgia and work disability: Is Fibromyalgia a disabling disorder?

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Novel Ways of Targeting Triple Negative Breast Cancer (TNBC) with the Latest Research - will it Improve Prognoses

Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities

Recent advances in targeted strategies for triple-negative breast cancer

Enhancement of cellular uptake of ellipticine by insulin preincubation.

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer

Data delivery workflow in an academic information warehouse.

A POSSIBLE CASE OF INSTINCTIVE BEHAVIOR IN THE WHITE RAT.

Druggable molecular targets of triple-negative breast cancer and prospects of therapeutic application

Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

The treatment landscape of triple-negative breast cancer

Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

Recent advances in therapeutic strategies for triple-negative breast cancer